Atrial Fibrillation and PCI

Slides:



Advertisements
Similar presentations
Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia Sindromi coronariche acute nei pazienti con fibrillazione.
Advertisements

EXAMINATION Objective Assess the safety and performance of a new-generation DES vs. a BMS in the setting of primary PCI for treatment of patients with.
Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial HORIZONS Trial.
WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.
1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.
The patient with atrial fibrillation who needs PCI
Denise Sutter, PharmD, BCPS
When should aspirin be dropped from triple therapy?
Addressing the Challenges in Primary and Secondary Stroke Prevention
Polypharmacy Anticoagulation: AF meets PCI
Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.
(p < for group 1 or 2 vs. group 3)
Learning Objectives. Learning Objectives Variable Response to Clopidogrel.
Preventing Thrombotic Complications in ACS: State of the Art
New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.
Anticoagulants in Interventional Cardiology:
Updates in Anticoagulation: What Did We Learn From ESC 2017?
NOACs, AF, and PCI: What Do the Latest Data Suggest?
Achieving Long-Term Protection Post-MI
When Is Adding Aspirin to NOACs Worth the Risk?
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
The ABCs of AF.
NOACs in Clinical Practice: Are They All the Same?
Applying New Data in Practice:
Appropriate Stroke Prevention Strategies in Atrial Fibrillation
Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.
Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)
PAD Patients vs Post-ACS Patients:
A New Era for NOACs:.
Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.
Table. Clinical Efficacy and Safety
Anticoagulation Highlights From the American Heart Association Meeting 2017.
New Perspectives in AF and PCI: Implications for the Practicing Physician.
Antithrombotics and PAD: A New Paradigm in Practice
New Perspectives in CAD and PAD: Weighing the Latest Evidence
What Has Been Tried and What Is True?
Oral Anticoagulants in AFa,b A Brief History.
Selecting NOACs for High-Risk Patients
Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI
The Essentials for Secondary Stroke Prevention
Anticoagulation Therapy in Patients Post-TAVR
Assessing the Risk for Stroke in Patients With Atrial Fibrillation
Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:
NOACS: Emerging data in ACS/IHD
AF and PCI in Practice.
Antithrombotic Protection in CAD and HF
TAVR and the Risk of Thrombosis
What Anticoagulant Registries Are Revealing
A Better Solution For Cancer Patients With VTE?
Atrial Fibrillation.
BASKET-SAVAGE Trial design: Patients with a SVG lesion were randomized to a DES (Taxus Liberte; n = 89) versus a BMS (Liberte; n = 84). All patients were.
Anticoagulation and Thrombosis Management
Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials
Duration of Dual Antiplatelet Therapy
Factor Xa Inhibitors in PAD
Antithrombotic Therapy in PAD
Updates in Anticoagulation: Key Sessions at ESC 2017
Antithrombotics in Arterial Disease: Focus on Coronary Disease
Elevated Admission Plasma Glucose Following ACS
The Challenge of AF and PCI: Practical Strategies to Improve Outcomes
Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial Renato D. Lopes, MD, PhD on behalf of the.
Factor Xa Inhibitors in Coronary Artery Disease
Improving Adherence to Antiplatelet Therapy After an ACS Event
The ABCs of AF.
5 Good Minutes on Atrial Fibrillation-related Stroke
Real-World Data in Cardiology: Focus on Atrial Fibrillation
Extraordinary Cases in Stroke Prevention
Antithrombotic Therapy in AF Patients Undergoing PCI
What's New in NOACs in AF?.
Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?
Presentation transcript:

Atrial Fibrillation and PCI

Program Goals

Overview

History

AHA/ACC Guidelines

ESC Guidelines

WOEST Bleeding Events

WOEST Death, MI, Stroke, TVR, and Stent Thrombosis

PIONEER AF-PCI Study Design

PIONEER AF-PCI Clinically Significant Bleeding

PIONEER Substudy Death or All-Cause Rehospitalization

PIONEER Substudy Rehospitalization

Implications of PIONEER Antithrombotic Therapy Postdischarge

RE-DUAL-PCI Trial Design

AUGUSTUS Trial

NOACs Plus Ticagrelor

GEMINI ACS

Stable Patient Requiring PCI

PIONEER AF-PCI MACE

Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)